BRAF and neoplasm: In terms of the oncologic outcomes, the association between MSI status and greater tumor burden in synchronous CRC suggests that synchronicity and BRAF mutations are risk factors for OS in patients with MSS CRC, but the disease-specific survival of MSI CRC patients was unaffected by synchronicity in a stage-adjusted analysis [33].